J.P. Morgan Private Wealth Advisors LLC Buys Shares of 19,325 Ascendis Pharma A/S (NASDAQ:ASND)

J.P. Morgan Private Wealth Advisors LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASNDFree Report) during the third quarter, according to the company in its most recent filing with the SEC. The firm purchased 19,325 shares of the biotechnology company’s stock, valued at approximately $1,810,000.

A number of other hedge funds also recently made changes to their positions in ASND. Envestnet Asset Management Inc. lifted its holdings in shares of Ascendis Pharma A/S by 14.4% during the 1st quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 282 shares in the last quarter. Rice Hall James & Associates LLC lifted its holdings in shares of Ascendis Pharma A/S by 35.1% during the 1st quarter. Rice Hall James & Associates LLC now owns 134,900 shares of the biotechnology company’s stock valued at $15,832,000 after acquiring an additional 35,039 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Ascendis Pharma A/S by 20.5% during the 1st quarter. Bank of New York Mellon Corp now owns 289,344 shares of the biotechnology company’s stock valued at $33,958,000 after acquiring an additional 49,298 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Ascendis Pharma A/S by 25.3% during the 1st quarter. BlackRock Inc. now owns 401,084 shares of the biotechnology company’s stock valued at $47,070,000 after acquiring an additional 80,988 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new position in shares of Ascendis Pharma A/S during the 1st quarter valued at $14,083,000.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wedbush lifted their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday. Cantor Fitzgerald lifted their target price on shares of Ascendis Pharma A/S from $152.00 to $173.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Morgan Stanley lifted their price target on shares of Ascendis Pharma A/S from $113.00 to $116.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 9th. Jefferies Financial Group began coverage on shares of Ascendis Pharma A/S in a research note on Wednesday, December 20th. They set a “buy” rating and a $150.00 price target on the stock. Finally, StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Monday, December 25th. Four investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Ascendis Pharma A/S has a consensus rating of “Moderate Buy” and a consensus target price of $154.75.

View Our Latest Research Report on ASND

Ascendis Pharma A/S Price Performance

ASND opened at $141.75 on Friday. The company has a 50-day moving average of $127.49 and a 200-day moving average of $105.61. The company has a market capitalization of $8.18 billion, a P/E ratio of -15.32 and a beta of 0.50. Ascendis Pharma A/S has a 1-year low of $64.33 and a 1-year high of $144.95. The company has a debt-to-equity ratio of 7.39, a quick ratio of 2.56 and a current ratio of 3.56.

Ascendis Pharma A/S Company Profile

(Free Report)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.

Featured Stories

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASNDFree Report).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.